Sep 19, 2025 05:00PM
Sep 19, 2025 05:00PM
Sep 5, 2025 07:51PM
Sep 5, 2025 07:50PM
Aug 11, 2025 07:28PM
Aug 11, 2025 07:28PM
Jul 30, 2025 08:21PM Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
Mar 3, 2025 08:00AM
Feb 26, 2024 04:05PM
Jan 31, 2024 05:06PM
Jan 24, 2024 05:55PM
Dec 20, 2023 12:54PM
May 2, 2023 06:00AM
Apr 18, 2023 06:44PM Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
Mar 28, 2023 07:00AM
Mar 20, 2023 08:28AM
Mar 8, 2023 07:45AM
Feb 6, 2023 08:00AM
Feb 6, 2023 08:00AM
Feb 3, 2023 06:00AM
Jan 19, 2023 04:50PM Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of C
Jan 12, 2023 01:14PM
Jan 12, 2023 06:00AM
Jan 9, 2023 03:34PM
Jan 5, 2023 09:19AM
Dec 22, 2022 02:00PM
Dec 15, 2022 07:29AM
Nov 30, 2022 05:43PM Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
Nov 24, 2022 09:18AM
Nov 22, 2022 09:20AM
Oct 14, 2022 01:34PM
Oct 6, 2022 10:18AM
Sep 28, 2022 07:00AM
Sep 16, 2022 06:00AM
Sep 14, 2022 06:00AM Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
Aug 16, 2022 06:00AM
Jul 25, 2022 10:57AM
Jun 24, 2022 11:41AM
Jun 6, 2022 01:54PM
May 31, 2022 07:00AM
May 26, 2022 10:15AM
May 16, 2022 10:48AM Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
Apr 25, 2022 04:42PM
Apr 18, 2022 09:43AM
Apr 11, 2022 05:54PM
Mar 29, 2022 08:45AM
Feb 24, 2022 08:00AM
Feb 15, 2022 04:26PM
Feb 14, 2022 06:00AM Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
Jan 18, 2022 09:02PM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All